Avalo Therapeutics (AVTX) Financials: History & Chart

Avalo Therapeutics, Inc.(AVTX)

Biotechnology · Wayne, PA

$13.67-0.93 (-6.37%)

Delayed quote: Oct 6, 2026, 10:55 AM EDT

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.

Wayne, PA

33 employees

www.avalotx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Garry A. Neil

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	59K	0.00	0.00	59K	0.00	0.00	0.00	192K	249K
Cost of Goods Sold	10.01M	0.00	17K	0.00	9.99M	10.66M	5.91M	87K	-714K
Gross Profit	-9.95M	0.00	-17K	59K	-9.99M	-10.66M	-5.91M	105K	963K
Gross Profit Margin	-16861.0%	N/A	N/A	100.0%	N/A	N/A	N/A	54.7%	386.7%
Total Operating Expenses	81.41M	31.52M	20.88M	19.80M	9.21M	8.66M	8.76M	13.42M	13.82M
Research & Development	64.35M	23.42M	14.05M	13.27M	13.62M	14.07M	9.12M	8.18M	9.54M
Selling, General & Administrative	27.05M	8.10M	6.84M	6.53M	5.58M	5.24M	5.55M	5.23M	4.29M
Operating Income (EBIT)	-91.36M	-31.52M	-20.90M	-19.74M	-19.20M	-19.32M	-14.67M	-13.31M	-12.86M
Operating Margin	-154844.1%	N/A	N/A	-33461.0%	N/A	N/A	N/A	-6932.8%	-5165.1%
Income Before Tax (EBT)	-100.16M	-36.34M	-19.62M	-13.59M	-30.61M	-20.75M	-13.14M	-35.23M	23.02M
Interest Income	5.67M	2.76M	803K	992K	1.12M	1.10M	1.15M	1.22M	964K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	-8.80M	-4.82M	1.28M	6.15M	-11.42M	-1.43M	1.53M	-21.91M	35.88M
Net Income	-100.33M	-36.36M	-19.63M	-13.72M	-30.63M	-20.77M	-13.15M	-35.34M	23.04M
Income Tax Expense	171K	18K	12K	130K	11K	16K	8K	114K	-14K
Net Profit Margin	-170055.9%	N/A	N/A	-23254.2%	N/A	N/A	N/A	-18405.7%	9251.8%
EBITDA	-91.23M	-31.48M	-20.88M	-19.73M	-19.14M	-19.18M	-14.53M	-13.24M	-12.83M
EBITDA Margin	-154630.5%	N/A	N/A	-33433.9%	N/A	N/A	N/A	-6897.4%	-5151.4%
Depreciation & Amortization	126K	34K	17K	16K	59K	134K	135K	68K	34K
EPS Basic	-4.74	-0.83	-0.98	-0.74	-2.19	-1.92	-1.25	N/A	2.83
EPS Diluted	-4.74	-0.83	-0.98	-0.74	-2.19	-1.92	-1.25	N/A	2.14
Weighted Average Basic Shares	43.60M	43.60M	20.11M	18.51M	14.00M	10.83M	10.51M	10.47M	5.55M
Weighted Average Diluted Shares	43.60M	43.60M	20.11M	18.51M	14.00M	10.83M	10.51M	10.47M	10.78M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	59K	441K	1.92M	18.05M	5.40M	6.70M	6.75M	18.33M
Cost of Goods Sold	0.00	-366K	1.28M	3.43M	1.49M	300K	-567K	7.48M
Gross Profit	59K	807K	640K	14.62M	3.91M	6.40M	7.32M	10.85M
Gross Profit Margin	100.0%	183.0%	33.3%	81.0%	72.4%	95.5%	108.4%	59.2%
Total Operating Expenses	72.98M	69.32M	27.99M	52.06M	86.04M	6.40M	23.45M	29.52M
Research & Development	50.08M	52.08M	13.78M	31.31M	59.84M	32.19M	11.76M	5.79M
Selling, General & Administrative	22.90M	17.24M	10.30M	20.71M	24.66M	19.76M	11.61M	19.20M
Operating Income (EBIT)	-72.92M	-68.51M	-27.35M	-37.44M	-82.13M	0.00	-16.14M	-39.31M
Operating Margin	-123601.7%	-15535.6%	-1421.6%	-207.4%	-1521.6%	0.0%	-239.1%	-214.5%
Income Before Tax (EBT)	-78.09M	-35.02M	-31.53M	-41.63M	-84.55M	-67.18M	-15.99M	-40.09M
Interest Income	4.35M	3.32M	N/A	N/A	N/A	49K	121K	16K
Interest Expense	N/A	N/A	3.42M	4.17M	2.39M	N/A	N/A	N/A
Other Income/Expense	-5.17M	33.50M	-4.18M	-4.19M	-2.41M	-67.18M	147K	55K
Net Income	-78.26M	-35.13M	-31.54M	-41.66M	-84.38M	-63.50M	-16.07M	-40.05M
Income Tax Expense	165K	114K	14K	28K	-196K	-2.79M	280K	-34K
Net Profit Margin	-132642.4%	-7965.8%	-1639.5%	-230.8%	-1563.1%	-947.9%	-238.1%	-218.5%
EBITDA	-72.58M	-68.34M	-27.19M	-37.27M	-80.48M	1.84M	-12.25M	-37.46M
EBITDA Margin	-123018.6%	-15497.3%	-1413.4%	-206.5%	-1490.9%	27.5%	-181.5%	-204.4%
Depreciation & Amortization	344K	169K	158K	166K	1.66M	1.84M	3.88M	1.85M
EPS Basic	-5.84	-4.32	-113.58	-1062.65	-2330.66	-2523.77	-819.74	-3317.28
EPS Diluted	-5.84	-3.26	-113.58	-1062.65	-2330.66	-2523.77	-819.74	-3317.28
Weighted Average Basic Shares	13.40M	8.13M	278K	39K	36K	26K	20K	12K
Weighted Average Diluted Shares	13.40M	10.78M	278K	39K	36K	26K	20K	12K

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.